| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $687,218 | 6 | 100 |
| Malabre Richard C | SVP, Chief Accounting Officer | 0 | $0 | 1 | $63,424 | $-63,424 |
| Grund Nicholas | Chief Commercial Officer | 0 | $0 | 1 | $116,804 | $-116,804 |
| Burke Steven Keith | SVP, Chief Medical Officer | 0 | $0 | 2 | $119,136 | $-119,136 |
| Butler John P. | CEO and President | 0 | $0 | 2 | $387,853 | $-387,853 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $687,218 worth of Akebia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $517,876 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $344,000 was made by Butler John P. (CEO and President) on 2019‑11‑20.
| 2025-03-03 | Sale | Butler John P. | CEO and President | 46,409 0.0217% | $1.83 | $84,928 | +14.72% | |
| 2025-03-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 7,144 0.0033% | $1.83 | $13,074 | +14.72% | |
| 2025-02-03 | Sale | Butler John P. | CEO and President | 144,250 0.062% | $2.10 | $302,925 | -2.36% | |
| 2025-02-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 50,506 0.0217% | $2.10 | $106,063 | -2.36% | |
| 2025-02-03 | Sale | Grund Nicholas | Chief Commercial Officer | 55,621 0.0239% | $2.10 | $116,804 | -2.36% | |
| 2025-02-03 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 30,202 0.013% | $2.10 | $63,424 | -2.36% | |
| 2024-05-13 | Sale | Dahan Michel | SVP, Chief Operating Officer | 34,840 0.0162% | $1.26 | $43,898 | +34.11% | |
| 2024-05-13 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 12,016 0.0056% | $1.26 | $15,140 | +34.11% | |
| 2024-02-29 | Sale | Butler John P. | CEO and President | 46,570 0.0249% | $1.58 | $73,581 | -7.28% | |
| 2024-02-29 | Sale | Dahan Michel | SVP, Chief Operating Officer | 8,661 0.0046% | $1.58 | $13,684 | -7.28% | |
| 2024-02-29 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 7,169 0.0038% | $1.58 | $11,327 | -7.28% | |
| 2024-02-29 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 5,974 0.0032% | $1.58 | $9,439 | -7.28% | |
| 2024-02-27 | Sale | Butler John P. | CEO and President | 37,733 0.0186% | $1.52 | $57,354 | -10.37% | |
| 2024-02-27 | Sale | Dahan Michel | SVP, Chief Operating Officer | 10,744 0.0053% | $1.52 | $16,331 | -10.37% | |
| 2024-02-27 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 8,367 0.0041% | $1.52 | $12,718 | -10.37% | |
| 2024-02-27 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 7,411 0.0036% | $1.52 | $11,265 | -10.37% | |
| 2024-02-01 | Sale | Butler John P. | CEO and President | 46,489 0.0254% | $1.68 | $78,102 | -15.50% | |
| 2024-02-01 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 24,311 0.0133% | $1.68 | $40,842 | -15.50% | |
| 2023-08-25 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 27,000 0.0145% | $1.15 | $31,050 | +9.57% | |
| 2023-05-25 | Sale | Dahan Michel | SVP, Chief Operating Officer | 95,478 0.0522% | $1.22 | $116,760 | +3.31% |
| Butler John P. | CEO and President | 2557921 0.9739% | $7.19M | 6 | 11 | <0.0001% |
| Burke Steven Keith | SVP, Chief Medical Officer | 809090 0.3081% | $2.27M | 1 | 15 | |
| Grund Nicholas | Chief Commercial Officer | 442579 0.1685% | $1.24M | 0 | 1 | |
| Malabre Richard C | SVP, Chief Accounting Officer | 280248 0.1067% | $787,496.88 | 0 | 1 | |
| Satter Muneer A | director | 3037042 1.1564% | $8.53M | 13 | 0 | <0.0001% |
| Novo A/S | 10 percent owner | 1516387 0.5774% | $4.26M | 1 | 0 | +3.18% |
| Dahan Michel | SVP, Chief Operating Officer | 672092 0.2559% | $1.89M | 0 | 20 | |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651243 0.248% | $1.83M | 1 | 23 | +3.18% |
| Spellman David A | SVP, CFO and Treasurer | 446483 0.17% | $1.25M | 0 | 6 | |
| Novartis Bioventures Ltd | 10 percent owner | 182590 0.0695% | $513,077.90 | 1 | 0 | +3.18% |
| Faulkingham Dell | SVP, CCO | 173841 0.0662% | $488,493.21 | 0 | 5 | |
| Amello Jason | SVP, CFO & Treasurer | 144642 0.0551% | $406,444.02 | 2 | 1 | <0.0001% |
| Tubridy Karen L | SVP, Chief Development Officer | 84679 0.0322% | $237,947.99 | 0 | 1 | |
| ADAMS ADRIAN | director | 63700 0.0243% | $178,997.00 | 1 | 0 | |
| GILMAN STEVEN C | 43430 0.0165% | $122,038.30 | 1 | 3 | ||
| Smith Cynthia | director | 37833 0.0144% | $106,310.73 | 1 | 1 | |
| Cotreau Violetta | SVP, Chief Accounting Officer | 29121 0.0111% | $81,830.01 | 0 | 2 | |
| GOWEN MAXINE | director | 24133 0.0092% | $67,813.73 | 1 | 1 | <0.0001% |
| Nash Duane | director | 21499 0.0082% | $60,412.19 | 0 | 14 | |
| Renaud Ronald C JR | director | 5000 0.0019% | $14,050.00 | 1 | 0 | <0.0001% |
| WYZGA MICHAEL S | director | 1500 0.0006% | $4,215.00 | 1 | 0 | +3.18% |
$3,596,906 | 112 | 13.42% | $833.57M | |
$571,084,134 | 44 | 4.33% | $911.67M | |
$97,176 | 41 | 42.84% | $664.19M | |
$678,065,999 | 37 | -13.32% | $628.78M | |
$61,763,245 | 35 | 16.21% | $787.96M | |
Akebia Therapeutics, Inc. (AKBA) | $54,828,550 | 26 | -13.88% | $738.01M |
$22,007,592 | 17 | -0.43% | $688.7M | |
$104,137,421 | 15 | 21.28% | $709.99M | |
$4,210,269 | 14 | -15.87% | $689.14M | |
$18,945,106 | 14 | -27.94% | $620.37M | |
$103,194,328 | 13 | 9.02% | $637.57M | |
$50,317,062 | 13 | -3.69% | $832.02M | |
$278,247,340 | 12 | 58.08% | $623.45M | |
$9,976,473 | 12 | 29.52% | $767.5M | |
$2,834,855 | 9 | 34.92% | $916.41M | |
$49,165,200 | 7 | 12.92% | $651.55M | |
$107,703,099 | 7 | 29.71% | $930.97M | |
$1,229,547 | 7 | 11.98% | $853.47M | |
$46,235,722 | 6 | -31.77% | $952.96M |
| Increased Positions | 93 | +102.2% | 35M | +51.08% |
| Decreased Positions | 32 | -35.16% | 739,936 | -1.09% |
| New Positions | 32 | New | 20M | New |
| Sold Out Positions | 4 | Sold Out | 88,727 | Sold Out |
| Total Postitions | 152 | +67.03% | 102M | +49.98% |
| Blackrock, Inc. | $37,564.00 | 5.87% | 15.33M | +234,538 | +1.55% | 2025-03-31 |
| Vanguard Group Inc | $26,666.00 | 4.17% | 10.88M | +813,902 | +8.08% | 2024-12-31 |
| State Street Corp | $15,447.00 | 2.42% | 6.3M | +3M | +83.78% | 2024-12-31 |
| Alerce Investment Management, L.P. | $14,082.00 | 2.2% | 5.75M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $11,748.00 | 1.84% | 4.8M | +40,631 | +0.85% | 2024-12-31 |
| Renaissance Technologies Llc | $9,368.00 | 1.47% | 3.82M | +105,727 | +2.84% | 2024-12-31 |
| Morgan Stanley | $4,386.00 | 0.69% | 1.79M | +701,159 | +64.39% | 2024-12-31 |
| Northern Trust Corp | $4,130.00 | 0.65% | 1.69M | +50,542 | +3.09% | 2024-12-31 |
| Citadel Advisors Llc | $3,386.00 | 0.53% | 1.38M | +1M | New | 2024-12-31 |
| Jacobs Levy Equity Management, Inc | $3,010.00 | 0.47% | 1.23M | -805,459 | -39.6% | 2024-12-31 |